Interstitial Lung Diseases (ILDs) encompass a broad category of roughly 200 lung disorders characterized by progressive scarring of lung tissue. Understanding ILDs is crucial for healthcare professionals due to their potential to cause severe lung damage and respiratory failure.
ILDs primarily affect the interstitium - the area around the lung's air sacs (alveoli). Inflammatory or fibrotic processes lead to thickening of this interstitial space, disrupting the exchange of oxygen and carbon dioxide. This results in progressive dyspnea and impaired lung function.
ILDs are categorized based on their etiology. Idiopathic Pulmonary Fibrosis (IPF) is the most common ILD, with unknown cause. Connective tissue diseases, such as Rheumatoid Arthritis or Systemic Lupus Erythematosus, can also lead to ILDs. Occupational and environmental exposures, certain medications, and radiation therapy are other potential causes.
Diagnosis of ILDs involves a detailed medical history, pulmonary function tests, imaging studies, and sometimes, lung biopsy. Management is primarily supportive, including pulmonary rehabilitation and oxygen therapy. Antifibrotic agents like pirfenidone and nintedanib are used in IPF. In severe cases, lung transplantation may be considered.
Prognosis varies widely among ILDs, with IPF having a particularly poor prognosis. Future research is focused on elucidating the pathophysiology of ILDs and developing targeted therapies to halt or reverse the fibrotic process.
Comprehending ILDs is essential for healthcare professionals, given their impact on respiratory function and quality of life. Accurate diagnosis and management can significantly influence patient outcomes. Continuous research is vital to further our understanding and improve therapeutic options for these challenging diseases.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation